Liver Cancer
=?ISO-8859-1?Q?MultiVu_Video_Feed:_The_New_England_Journa? =?ISO-8
Published in Medical Letter on the CDC and FDA, August 10th, 2008
A recent study published in The New England Journal of Medicine showed results of a Phase 3 trial demonstrating that Nexavar=AE (sorafenib) tablets decreased the absolute risk of death by 31 percent in patients with unresectable hepatocellular carcinoma (HCC), or liver cancer, versus patients who received placebo. This represents a 44 percent improvement in median overall survival for patients treated with Nexavar. Based on the strength of these data, Nexavar was approved for HCC by the European Agency for the Evaluation of Medicinal Products (EMEA)...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Norwegian Institute of Public Health
Vaccinated infants well-protected against severe pneumococcal infection in Norway - Bayer HealthCare Pharmaceuticals; Onyx Pharmaceuticals, Inc.
The New England Journal of Medicine Publishes Nexavar Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer - Dementia
Reports from Harvard University, Medical Department advance knowledge in dementia - Life Sciences
Researchers from New York University provide details of new studies and findings in the area of life sciences - Liver Cancer
The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer - Pharmacokinetics
Study findings from C.H.D.R. Serra et al broaden understanding of pharmacokinetics - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
